The different telomere lengths in basal and squamous cell carcinomas also differ between the nontransplant and renal transplant population

Perrem, Kilian; Lynch, Ailish; Nooh, Fatima al; Leader, M.; Kay, Elaine W.

doi:10.1016/j.humpath.2007.11.008

Cited by 8 publications

(9 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results showed that Ab 3 (NCL-L-hTERT antibody) was not absorbed any more with the nucleolin peptide than were the other anti-hTERT antibodies. In agreement with other researchers (27,70,71,(88)(89)(90)(91)(92)(93)(94)(95)(96)(97) and despite the objection raised by Wu et al (64) the Ab 3 proved suitable for hTERT detection. Mitsuishi et al (98) not only confirmed the consideration of Wu et al (64), but also found excellent correlation between nucleolin expression and telomerase activity levels in Bowens's disease and in normal sunexposed skin.…”

Section: Comparison Of Htert Results In Basal Cell Carcinomas and Squsupporting

confidence: 91%

“…Since then many researchers have applied this protocol for proof of telomerase activation in basal cell carcinomas (23,24,26,(38)(39)(40)(41)45,47,48,50). Up to now only a few studies with in situ localization of hTERT in BCCs have been published: immunohistochemical studies by Park et al (25), Brasnac et al (70) and Perrem et al (71), an in situ hybridization study by Guttman-Yassky et al (72) and a fluorescence in situ hybridization study by Perrem et al (71). Immunohistochemical investigations on cryo sections are missing altogether.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Localization of telomerase hTERT protein in frozen sections of basal cell carcinomas (BCC) and tumor margin tissues

Fabricius

Kruse-Boitschenko²,

Khoury³

et al. 2009

Int J Oncol

View full text Add to dashboard Cite

Abstract.In previous studies we demonstrated telomerase activity in frozen tissues from BCC and their tumor-free margins by the PCR ELISA. In this study we examined in the same frozen sections immunohistochemical presence of hTERT in the nucleus. After fixation in acetone and methanol followed by steaming we used for visualization the antigenantibody reactions by APAAP. This was the best method of preparation of the frozen sections in our preliminary hTERT-study with squamous cell carcinomas. This study was supplemented with antibodies against Ki-67, nucleolin, common leucocyte antigen CD45 and mutated p53. The immunoreactive scores were determined and included the comparison with telomerase activity. The investigation of hTERT expression was performed in the tissues of 41 patients with BCC and control tissues of 14 patients without tumor. Eleven commercial antibodies were used for a nuclear staining of hTERT expression. With the anti-hTERT antibodies we looked for both satisfactory distribution and intensity of immunohistochemical labeling in the carcinomas and in the squamous epithelia of the tumor centers, of the tumor-free margins and of the control tissues. The hTERT expression in the BCC was distributed heterogeneously. The score values established by the anti-hTERT antibodies used were variably or significantly increased. In the stroma they tended to be negative, so we disregarded stroma hTERT. Proof of hTERT did not differ uniformly from telomerase activity. We compared the high with the lower median hTERT values in the Kaplan-Meier curve. Patients with lower hTERT scores in the center or tumor margin as shown by some of the antibodies suffered relapse earlier. Finally, we compared the hTERT expression in BCC tissues with the hTERT scores in HNSCC tissues from our previous study. Only one anti-hTERT antibody (our Ab 7) yielded significantly higher scores in BCC than in HNSCC.

show abstract

Section: Comparison Of Htert Results In Basal Cell Carcinomas and Squsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Localization of telomerase hTERT protein in frozen sections of basal cell carcinomas (BCC) and tumor margin tissues

Fabricius

Kruse-Boitschenko²,

Khoury³

et al. 2009

Int J Oncol

View full text Add to dashboard Cite

show abstract

“…In contrast, other authors found that longer telomeres in PBL are protective for BCC [2,86] and SCC [2]. Telomere length has also been evaluated by fluorescent in situ hybridization (FISH) showing that higher telomere length in BCC is significantly higher than in SCC [93].…”

Section: Telomerase Promoter Mutations In Skin Cancersmentioning

confidence: 99%

Telomerase promoter mutations in cancer: an emerging molecular biomarker?

et al. 2014

View full text Add to dashboard Cite

Cell immortalization has been considered for a long time as a classic hallmark of cancer cells. Besides telomerase reactivation, such immortalization could be due to telomere maintenance through the "alternative mechanism of telomere lengthening" (ALT) but the mechanisms underlying both forms of reactivation remained elusive. Mutations in the coding region of telomerase gene are very rare in the cancer setting, despite being associated with some degenerative diseases. Recently, mutations in telomerase (TERT) gene promoter were found in sporadic and familial melanoma and subsequently in several cancer models, notably in gliomas, thyroid cancer and bladder cancer. The importance of these findings has been reinforced by the association of TERT mutations in some cancer types with tumour aggressiveness and patient survival. In the first part of this review, we summarize the data on the biology of telomeres and telomerase, available methodological approaches and nonneoplastic diseases associated with telomere dysfunction. In the second part, we review the information on telomerase expression and genetic alterations in the most relevant types of cancer (skin, thyroid, bladder and central nervous system) on record, and discuss the value of telomerase as a new biomarker with impact on the prognosis and survival of the patients and as a putative therapeutic target.

show abstract

“…Thus, tacrolimus treatment augments skin carcinogenesis via chromosomal aberrations whereas CsA targets an entirely different pathway. In addition, alterations in telomere length and telomerase activity were found to influence the incidence of both BCCs and SCCs in immune suppressed populations [35,36]. …”

Section: Immunesuppressive Drugs and Skin Cancer Pathogenesismentioning

confidence: 99%

Pathogenesis of nonmelanoma skin cancers in organ transplant recipients

Athar

Walsh

Kopelovich

et al. 2011

Archives of Biochemistry and Biophysics

View full text Add to dashboard Cite

Nonmelanoma skin cancer (NMSC) is the most common human cancer, with an incidence of more than 1.2 million per year in the U.S.A. The risk for the development of NMSCs increases by approximately 10-250 fold in chronically immune suppressed organ transplant recipients (OTRs). Solar UVB is the most common etiologic factor in the development of this neoplasm, both in immune competent and immune suppressed populations. This review provides a description of NMSC in OTRs. It also provides an account of the various immunologic and non-immunedependent mechanisms involved in the pathogenesis and progression of NMSCs in OTRs. Finally, this review addresses possible strategies for the prevention of this cancer, particularly focusing on the aspects that may be incorporated to prevent negative effects of chemopreventive chemicals on graft survival.

show abstract

The different telomere lengths in basal and squamous cell carcinomas also differ between the nontransplant and renal transplant population

Cited by 8 publications

References 17 publications

Localization of telomerase hTERT protein in frozen sections of basal cell carcinomas (BCC) and tumor margin tissues

Localization of telomerase hTERT protein in frozen sections of basal cell carcinomas (BCC) and tumor margin tissues

Telomerase promoter mutations in cancer: an emerging molecular biomarker?

Pathogenesis of nonmelanoma skin cancers in organ transplant recipients

Contact Info

Product

Resources

About